Novonix Limited Logo

Novonix Limited

NVX

(1.5)
Stock Price

1,46 USD

-8.71% ROA

-36.59% ROE

-5.47x PER

Market Cap.

211.377.023,00 USD

16.85% DER

0% Yield

-657.14% NPM

Novonix Limited Stock Analysis

Novonix Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Novonix Limited Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.61x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (17%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Assets Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

4 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

5 ROE

Negative ROE (-15.6%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

6 ROA

The stock's ROA (-8.71%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

7 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Novonix Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Novonix Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Novonix Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Novonix Limited Revenue
Year Revenue Growth
2015 0
2016 62.096 100%
2017 1.595.457 96.11%
2018 1.272.550 -25.37%
2019 2.922.620 56.46%
2020 3.927.501 25.59%
2021 3.927.501 0%
2022 8.417.763 53.34%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Novonix Limited Research and Development Expenses
Year Research and Development Expenses Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 4.843.134 100%
2022 7.040.367 31.21%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Novonix Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2015 731.890
2016 4.025.196 81.82%
2017 6.715.304 40.06%
2018 7.223.704 7.04%
2019 10.132.848 28.71%
2020 11.820.255 14.28%
2021 11.820.255 0%
2022 60.329.931 80.41%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Novonix Limited EBITDA
Year EBITDA Growth
2015 -954.786
2016 -4.258.771 77.58%
2017 -7.047.081 39.57%
2018 -15.326.775 54.02%
2019 -9.150.556 -67.5%
2020 -9.992.822 8.43%
2021 -9.992.822 0%
2022 -63.594.984 84.29%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Novonix Limited Gross Profit
Year Gross Profit Growth
2015 0
2016 8.328 100%
2017 891.841 99.07%
2018 753.403 -18.38%
2019 2.067.027 63.55%
2020 3.198.874 35.38%
2021 3.198.874 0%
2022 5.411.786 40.89%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Novonix Limited Net Profit
Year Net Profit Growth
2015 -928.844
2016 -4.714.927 80.3%
2017 -7.583.473 37.83%
2018 -18.294.193 58.55%
2019 -13.762.000 -32.93%
2020 -13.581.232 -1.33%
2021 -14.467.044 6.12%
2022 -73.472.159 80.31%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Novonix Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Novonix Limited Free Cashflow
Year Free Cashflow Growth
2015 -897.891
2016 -6.154.974 85.41%
2017 -9.109.478 32.43%
2018 -2.419.025 -276.58%
2019 2.735.502 188.43%
2020 -1.465.114 286.71%
2021 -25.798.322 94.32%
2023 -13.017.000 -98.19%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Novonix Limited Operating Cashflow
Year Operating Cashflow Growth
2015 -883.055
2016 -4.710.837 81.25%
2017 -7.470.162 36.94%
2018 -1.096.624 -581.2%
2019 6.404.343 117.12%
2020 18.193.230 64.8%
2021 -6.139.977 396.31%
2023 -8.950.000 31.4%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Novonix Limited Capital Expenditure
Year Capital Expenditure Growth
2015 14.836
2016 1.444.137 98.97%
2017 1.639.317 11.91%
2018 1.322.402 -23.97%
2019 3.668.841 63.96%
2020 19.658.344 81.34%
2021 19.658.344 0%
2023 4.067.000 -383.36%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Novonix Limited Equity
Year Equity Growth
2014 2.239.848
2015 2.025.887 -10.56%
2016 15.438.755 86.88%
2017 23.219.594 33.51%
2018 11.046.291 -110.2%
2019 45.715.665 75.84%
2020 138.543.459 67%
2021 138.543.459 0%
2022 364.343.319 61.97%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Novonix Limited Assets
Year Assets Growth
2014 2.305.673
2015 2.184.150 -5.56%
2016 26.108.391 91.63%
2017 25.143.348 -3.84%
2018 24.455.766 -2.81%
2019 51.710.872 52.71%
2020 152.414.252 66.07%
2021 152.414.252 0%
2022 439.561.402 65.33%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Novonix Limited Liabilities
Year Liabilities Growth
2014 65.825
2015 158.263 58.41%
2016 10.669.636 98.52%
2017 1.923.754 -454.63%
2018 13.409.475 85.65%
2019 5.995.207 -123.67%
2020 13.870.793 56.78%
2021 13.870.793 0%
2022 75.218.083 81.56%

Novonix Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.04
Net Income per Share
-0.32
Price to Earning Ratio
-5.47x
Price To Sales Ratio
50.22x
POCF Ratio
-2.48
PFCF Ratio
-3.04
Price to Book Ratio
0.55
EV to Sales
15.6
EV Over EBITDA
-2.07
EV to Operating CashFlow
-0.81
EV to FreeCashFlow
-0.95
Earnings Yield
-0.18
FreeCashFlow Yield
-0.33
Market Cap
0,21 Bil.
Enterprise Value
0,07 Bil.
Graham Number
4.73
Graham NetNet
1.11

Income Statement Metrics

Net Income per Share
-0.32
Income Quality
159.66
ROE
-0.16
Return On Assets
-0.25
Return On Capital Employed
-0.26
Net Income per EBT
1
EBT Per Ebit
0.99
Ebit per Revenue
-6.64
Effective Tax Rate
0.02

Margins

Sales, General, & Administrative to Revenue
7.17
Research & Developement to Revenue
0.84
Stock Based Compensation to Revenue
-1.2
Gross Profit Margin
-3.6
Operating Profit Margin
-6.64
Pretax Profit Margin
-6.59
Net Profit Margin
-6.57

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.7
Free CashFlow per Share
-0.6
Capex to Operating CashFlow
-0.14
Capex to Revenue
2.76
Capex to Depreciation
-8
Return on Invested Capital
-0.08
Return on Tangible Assets
-0.09
Days Sales Outstanding
308.56
Days Payables Outstanding
934.37
Days of Inventory on Hand
659.61
Receivables Turnover
1.18
Payables Turnover
0.39
Inventory Turnover
0.55
Capex per Share
0.1

Balance Sheet

Cash per Share
1,72
Book Value per Share
3,14
Tangible Book Value per Share
2.98
Shareholders Equity per Share
3.14
Interest Debt per Share
0.54
Debt to Equity
0.17
Debt to Assets
0.14
Net Debt to EBITDA
4.58
Current Ratio
20.56
Tangible Asset Value
0,35 Bil.
Net Current Asset Value
0,16 Bil.
Invested Capital
0.17
Working Capital
0,22 Bil.
Intangibles to Total Assets
0.04
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
2294153.5
Debt to Market Cap
0.29

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Novonix Limited Dividends
Year Dividends Growth

Novonix Limited Profile

About Novonix Limited

Novonix Limited develops and supplies battery materials, equipment, and services to the lithium-ion battery market in North America. It operates through three segments: Graphite Exploration and Mining, Battery Technology, and Battery Materials. The Graphite Exploration and Mining segment explores for graphite in Australia. The Battery Technology segment develops battery cell testing equipment and batteries, and consulting services. The Battery Materials segment develops and manufactures battery anode materials. The company is also involved in the investment and battery testing activities. Novonix Limited has strategic alliance with Harper International Corporation to develop specialized furnace technology that would enhance Novonix's synthetic graphite manufacturing process; and partnership with Emera Technologies to develop and manufacture energy storage systems for community microgrids. The company was formerly known as Graphitecorp Limited and changed its name to Novonix Limited in July 2017. Novonix Limited was incorporated in 2012 and is headquartered in Brisbane, Australia.

CEO
Dr. John Christopher Burns
Employee
0
Address
Central Plaza Two
Brisbane, 4000

Novonix Limited Executives & BODs

Novonix Limited Executives & BODs
# Name Age
1 Dr. John Christopher Burns
Chief Executive Officer
70
2 Ms. Suzanne Margaret Yeates B.Bus, C.A.
Financial Controller & Company Secretary
70
3 Mr. Nicholas Liveris
Chief Financial Officer
70
4 Ms. Rashda M. Buttar
Chief Legal & Administrative Officer
70
5 Mr. Darcy Macdougald
Chief Operating Officer
70
6 Mr. Danny Deas
President of Anode Materials
70
7 Prof. Jeffrey Dahn
Chief Scientific Advisor
70
8 Lori Mcleod
President of Battery Technology Solutions
70

Novonix Limited Competitors